Powder: -20°C for 3 years | In solvent: -80°C for 1 year
LS-102, a selective E3 ubiquitin ligase synoviolin (Syvn1) inhibitor, effectively inhibits the autoubiquitination of synoviolin, exhibiting an IC50 value of 35 μM. This compound shows promise for the treatment of rheumatoid arthritis.
Description | LS-102, a selective E3 ubiquitin ligase synoviolin (Syvn1) inhibitor, effectively inhibits the autoubiquitination of synoviolin, exhibiting an IC50 value of 35 μM. This compound shows promise for the treatment of rheumatoid arthritis. |
In vitro | LS-102 suppresses polyubiquitination of target proteins of Syvn1, including nuclear factor erythroid 2-related factor 2 (NRF2), V247M α-sarcoglycan mutant, and PGC-1β. LS-102 inhibits E3 ligase activity of Synoviolin (Syvn1)[2].LS-102 inhibits proliferation of RSCs with an IC50 of 5.4 μM[1].?LS-102 suppresses proliferation of rheumatoid synovial cells (RSCs) in a Syvn1-dependent manner. |
In vivo | LS-102 (1.3-4 mg/kg; i.p.; daily for 4 weeks) reduces clinical severity scores in a CIA model[1]. |
Molecular Weight | 452.6 |
Formula | C24H36N8O |
CAS No. | 1456891-34-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
LS-102 1456891-34-1 Others LS 102 LS102 inhibitor inhibit